A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun (2017) 0.80

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell (2016) 0.78

B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway. J Cancer (2017) 0.78

Aptamers for CD Antigens: From Cell Profiling to Activity Modulation. Mol Ther Nucleic Acids (2016) 0.78

Immunotherapy in small-cell lung cancer: at what point are we? Ann Transl Med (2016) 0.75

Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. Acta Pharmacol Sin (2017) 0.75

Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton. Neoplasia (2017) 0.75

Myeloid-derived suppressor cells and their role in pancreatic cancer. Cancer Gene Ther (2016) 0.75

Tumor necrosis factor alpha secreted from oral squamous cell carcinoma contributes to cancer pain and associated inflammation. Pain (2017) 0.75

What's New in SCLC? A Review. Neoplasia (2017) 0.75

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42

PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24

Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74

PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49

Interactions between the microbiota and the immune system. Science (2012) 10.45

Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86

Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63

Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 6.97

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80

PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17

The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 5.50

Aptamers as therapeutics. Nat Rev Drug Discov (2010) 5.36

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol (2011) 5.30

Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem (1999) 5.22

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13

Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10

Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 5.05

Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest (2013) 4.96

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol (2014) 4.37

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science (2015) 4.23

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol (2015) 4.04

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 3.77

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol (2013) 3.74

Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med (2003) 3.21

PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett (2004) 2.77

PD-1 signaling in primary T cells. Immunol Rev (2009) 2.66

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 2.65

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol (2010) 2.51

Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol (2010) 2.44

Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17

Intestinal commensal microbes as immune modulators. Cell Host Microbe (2012) 2.07

PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol (2014) 2.03

Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer (2012) 1.93

Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res (2013) 1.78

MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J Immunol (2009) 1.76

The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci (2011) 1.67

B7 family checkpoint regulators in immune regulation and disease. Trends Immunol (2013) 1.53

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene (2008) 1.41

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov (2016) 1.34

Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr (2008) 1.24

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res (2015) 1.18

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Oncologist (2016) 1.18

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer (2015) 1.17

PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol (2015) 1.16

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med (2014) 1.06

PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol (2015) 1.06

Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol (2004) 1.01

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res (2015) 1.01

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. Oncologist (2016) 0.99

Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. PLoS One (2015) 0.97

BAT monoclonal antibody immunotherapy of human metastatic colorectal carcinoma in mice. Cancer Lett (2005) 0.96

Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma. Int J Oncol (2001) 0.94

Maintaining poise: commensal microbiota calibrate interferon responses. Immunity (2012) 0.90

Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. Am J Health Syst Pharm (2016) 0.89

Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs (2016) 0.89

The prognostic significance of PD-L1 in bladder cancer. Oncol Rep (2015) 0.89

Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. Angew Chem Int Ed Engl (2015) 0.88

Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Transl Lung Cancer Res (2015) 0.88

Programmed death 1 immune checkpoint inhibitors. Clin Adv Hematol Oncol (2015) 0.87

Prevention of melanoma metastases in lungs of BAT treated and peptide immunized mice. Int J Oncol (2006) 0.83

BAT mAb induces lymphopoiesis in nude mice. Int Immunol (2005) 0.83

Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery. Cancer Immunol Res (2015) 0.82

Pembrolizumab for treatment of refractory melanoma. Lancet Oncol (2014) 0.81

From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discov Today (2016) 0.79

Pembrolizumab: A Review in Advanced Melanoma. Drugs (2016) 0.78

Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol (2015) 0.77

Antibodies are challenged. Indian J Med Sci (2010) 0.77

Basics of PD-1 in self-tolerance, infection, and cancer immunity. Int J Clin Oncol (2016) 0.77